Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Work In Process (2023 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Work In Process for 3 consecutive years, with $387000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Work In Process fell 53.93% to $387000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $387000.0, a 53.93% decrease, with the full-year FY2024 number at $1.2 million, up 13.22% from a year prior.
  • Work In Process was $387000.0 for Q3 2025 at Rhythm Pharmaceuticals, down from $767000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.5 million in Q3 2023 to a low of $387000.0 in Q3 2025.
  • A 3-year average of $1.7 million and a median of $1.5 million in 2024 define the central range for Work In Process.
  • Biggest YoY gain for Work In Process was 13.22% in 2024; the steepest drop was 75.99% in 2024.
  • Rhythm Pharmaceuticals' Work In Process stood at $1.1 million in 2023, then rose by 13.22% to $1.2 million in 2024, then tumbled by 69.04% to $387000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Work In Process are $387000.0 (Q3 2025), $767000.0 (Q2 2025), and $1.7 million (Q1 2025).